This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Malic acid
- DrugBank Accession Number
- DB12751
- Background
Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Malic acid (DB12751)
- Weight
- Average: 134.0874
Monoisotopic: 134.021523302 - Chemical Formula
- C4H6O5
- Synonyms
- Malic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Acerbine - Lösung Malic acid (21.5 mg/g) + Benzoic acid (1.5 mg/g) + Salicylic acid (0.4 mg/g) Solution Topical Pharmazeutische Fabrik Montavit Gmb H 1972-08-28 Not applicable Austria 
Acerbine - Salbe Malic acid (7 mg/g) + Benzoic acid (0.5 mg/g) + Salicylic acid (0.133 mg/g) Ointment Topical Pharmazeutische Fabrik Montavit Gmb H 1977-11-17 Not applicable Austria AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 ML Malic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey 
AKE 1100 GLUKOZLU IV SOLOSYONU, 500 ML Malic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey AMINOPLASMAL-10% E INFUSION Malic acid (1.01 g/l) + Acetylcysteine (0.5 g/l) + Alanine (13.7 g/l) + Arginine (9.2 g/l) + Asparagine (3.27 g/l) + Aspartic acid (1.3 g/l) + Glutamic acid (4.6 g/l) + Glycine (7.9 g/l) + Histidine (5.2 g/l) + Isoleucine (5.1 g/l) + Leucine (8.9 g/l) + Lysine hydrochloride (5.6 g/l) + Magnesium acetate (0.56 g/l) + Methionine (3.8 g/l) + N-acetyltyrosine (1 g/l) + Ornithine hydrochloride (2.51 g/l) + Phenylalanine (5.1 g/l) + Potassium acetate (2.45 g/l) + Proline (8.9 g/l) + Serine (2.4 g/l) + Sodium acetate (3.95 g/l) + Sodium hydroxide (0.2 g/l) + Sodium phosphate, monobasic (1.4 g/l) + Threonine (4.1 g/l) + Tryptophan (1.8 g/l) + Tyrosine (0.3 g/l) + Valine (4.8 g/l) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable Singapore AMINOPLASMAL-5% E INFUSION Malic acid (1.01 g/1000ml) + Acetylcysteine (0.25 g/1000ml) + Alanine (6.85 g/1000ml) + Arginine (4.6 g/1000ml) + Asparagine (1.64 g/1000ml) + Aspartic acid (0.65 g/1000ml) + Glutamic acid (2.3 g/1000ml) + Glycine (3.95 g/1000ml) + Histidine (2.6 g/1000ml) + Isoleucine (2.55 g/1000ml) + Leucine (4.45 g/1000ml) + Lysine hydrochloride (2.8 g/1000ml) + Magnesium acetate (0.56 g/1000ml) + Methionine (1.9 g/1000ml) + N-acetyltyrosine (0.35 g/1000ml) + Ornithine hydrochloride (1.25 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium acetate (2.45 g/1000ml) + Proline (4.45 g/1000ml) + Serine (1.2 g/1000ml) + Sodium acetate (3.95 g/1000ml) + Sodium hydroxide (0.2 g/1000ml) + Sodium phosphate, monobasic (1.4 g/1000ml) + Threonine (2.05 g/1000ml) + Tryptophan (0.9 g/1000ml) + Tyrosine (0.3 g/1000ml) + Valine (2.4 g/1000ml) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable Singapore AMINOVEN INFANT 10% Malic acid (2.62 g) + Acetylcysteine (0.7 g) + Alanine (9.3 g) + Arginine (7.5 g) + Glycine (4.15 g) + Histidine (4.76 g) + Isoleucine (8 g) + Leucine (13 g) + Lysine acetate (12 g) + Methionine (3.12 g) + N-acetyltyrosine (5.176 g) + Phenylalanine (3.75 g) + Proline (9.71 g) + Serine (7.67 g) + Taurine (0.4 g) + Threonine (4.4 g) + Tryptophan (2.01 g) + Valine (9 g) Solution Intravenous Fresenius Kabi Austria GmbH 2006-11-10 Not applicable Colombia 
Kalium-L-malat "Fresenius" 1 molar - Infusionszusatz - Ampullen Malic acid (2.682 g/20ml) + Potassium hydroxide (1.32 g/20ml) Solution Intravenous Fresenius Kabi Austria Gmb H 1988-09-08 Not applicable Austria Sterofundin HG 5 - Infusionslösung Malic acid (1.34 g) + Calcium chloride dihydrate (0.18 g) + Dextrose, unspecified form (50 g) + Magnesium chloride hexahydrate (0.1 g) + Potassium chloride (0.15 g) + Sodium chloride (3.5 g) + Sodium hydroxide (0.4 g) Solution Parenteral B. Braun Melsungen Ag 1969-09-25 Not applicable Austria STEROFUNDIN ISO Malic acid (0.67 g/L) + Calcium chloride dihydrate (0.37 g/1L) + Magnesium chloride hexahydrate (0.2 g/1L) + Potassium chloride (0.3 g/L) + Sodium acetate trihydrate (3.27 g/1L) + Sodium chloride (6.8 g/1L) Solution Parenteral บริษัท บี.บราวน์ (ประเทศไทย) จำกัด 2010-03-30 Not applicable Thailand 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Beta hydroxy acids and derivatives
- Direct Parent
- Beta hydroxy acids and derivatives
- Alternative Parents
- Short-chain hydroxy acids and derivatives / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Fatty acid / Hydrocarbon derivative
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- C4-dicarboxylic acid, 2-hydroxydicarboxylic acid (CHEBI:6650)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 817L1N4CKP
- CAS number
- 6915-15-7
- InChI Key
- BJEPYKJPYRNKOW-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)
- IUPAC Name
- 2-hydroxybutanedioic acid
- SMILES
- OC(CC(O)=O)C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000744
- KEGG Compound
- C00711
- PubChem Compound
- 525
- PubChem Substance
- 347828940
- ChemSpider
- 510
- BindingDB
- 92495
- 29209
- ChEBI
- 6650
- ChEMBL
- CHEMBL1455497
- Wikipedia
- Malic_acid
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2, 3 Completed Treatment Depression / Dry Mouth / High Blood Pressure (Hypertension) 1 Not Available Completed Treatment Malignancies, Hematologic 1 Not Available Recruiting Treatment Dry Mouth 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Topical Ointment Topical Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution Parenteral Solution Intravenous Solution Intravenous 0.3675 g/1000ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 218.0 mg/mL ALOGPS logP -0.87 ALOGPS logP -1.1 ChemAxon logS 0.21 ALOGPS pKa (Strongest Acidic) 3.2 ChemAxon pKa (Strongest Basic) -3.9 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 94.83 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 24.88 m3·mol-1 ChemAxon Polarizability 10.91 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at October 21, 2016 00:01 / Updated at February 21, 2021 18:53